The Early Phase I clinical investigation of Ginger in treatment of NAFLD in patients with type 2 diabetes mellitus (NCT02289235) is in progress to test whether Ginger takes effects on the liver biomarkers (ALT, AST, and γ-glutamyl transpeptidase) and fatty liver score in fibro-scan. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.